Navigation Links
Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
Date:2/9/2011

GENEVA, Feb. 9, 2011 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company specializing in the rapid development and engineering of high yield and stable mammalian cell-lines for therapeutic protein manufacturing, announced today a major expansion of the company's Swiss-based laboratories and staff.  The additional space comes in response to the increasing global demand for recombinant therapeutic proteins as well as outsourcing support for the rapid production of recombinant proteins.

Selexis' Swiss-based facilities now total over 13,000 square feet, a 100% increase over the former space.  This is the second major expansion for the company that originally opened in 2001 as a spin-off from the University of Lausanne.  The additional space houses larger laboratory and production functions, including a protein purification unit for small batches of purified research/pre-clinical proteins.  The Company will also increase the R&D and sales staff by more than 30%. The additional facilities and staff will enable Selexis to effectively service current and future client demands, while providing needed capacity to further expand its leading Selexis SURE™ Technology Platform and services.

"Our expansion was prompted by the global demand for outsourcing cell line engineering, the manufacturing of recombinant protein for pre-clinical research and interest in biosimilars as well as emerging technologies such as protein scaffolds. This investment will enable Selexis to provide even greater value to our current and future customers," said Dr. Igor Fisch, CEO, Selexis SA. "Our new laboratory space and staff represents a significant expansion for our business."

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins.  The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis VS™ Variant Screening and the proprietary Selexis CHO-M cell line.

For more information, visit http://www.selexis.com Media Contact:Robert Meister, Head of Marketing CommunicationsSelexis SA+1-602-953-1716robert.meister@selexis.com http://www.selexis.com
'/>"/>

SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. US Neuropathic Pain Market Value Doubles to $5 Billion by 2018
4. SleepQuest Compliance Again Doubles Industry Average
5. Carbon nanotube avalanche process nearly doubles current
6. Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
7. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. RainDance Technologies Appoints Olex Vice President, System Development
10. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
11. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical Informatics Association ... Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans ... policy. AMIA recommended that NIH earmark funding for researchers to produce and execute ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a ... The tremendous growth is accounted to two main factors. The first is ... expanding network of vendors supplying FireflySci products all around the world. , 2016 was ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
Breaking Biology Technology:
(Date:1/6/2017)... Jan. 5, 2017  SomaLogic announced today that ... Alliance" established by iCarbonX, the China ... a "Global Digital Health Ecosystem that can define ... of individual,s biological, behavioral and psychological data, the ... the companies, SomaLogic will provide proteomics data and ...
(Date:1/3/2017)... Onitor, provider of digital health technology for ... innovative biometric data-driven program designed to aid weight loss ... 2017 Consumer Electronics Show (CES) in Las ... the World Health Organization (WHO), have identified lifestyle risks ... are overweight or obese. WHO also states that more ...
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
Breaking Biology News(10 mins):